DT07 Rec'd PET/PT0 1 6 DEC 2004

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER 082368-001500US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

PRIORITY DATE CLAIMED

INTERNATIONAL APPLICATION NO. PCT/JP03/07721

Paper copy of the Sequence Listing; and

INTERNATIONAL FILING DATE June 18, 2003

June 18, 2002

TITLE	OF INV	/ENTION						
PRIM	ARY	CULTURED ADIPOCYTES FOR GENE THERAPY						
		S) FOR DO/EO/US						
Masa	shi IT	O and Yasushi SAITO						
Applica	ant here	with submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. 🛛	This is	a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. 🔲	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3. 🗌	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include item (5), (6), (9) and (21) indicated below.							
4. 🛛	The U	The US has been elected (Article 31).						
5. 🛛	А сору	y of the International Application as filed (35 U.S.C. 371(c)(2))						
	a. 🔲	is attached hereto (required only if not communicated by the International Bureau).						
	b. 🛚	has been communicated by the International Bureau						
	c. 🛚	is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. 🛛	An En	glish language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	a. 🛚	is attached hereto.						
	b. 🔲	has been previously submitted under 35 U.S.C. 154(d)(4).						
7. 🛛	Amend	dments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	а. 🗌	are attached hereto (required only if not communicated by the International Bureau).						
	b. 🗆	have been communicated by the International Bureau.						
	c. 🔲	have not been made; however, the time limit for making such amendments has NOT expired.						
	d. 🛛	have not been made and will not be made.						
8. 🔲	An En	glish language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9. 🗆	An oat	th or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10. 🔲		English language translation of the annexes of the International Preliminary Examination Report under PCT sle 36 (35 U.S.C. 371(c)(5)).						
	Items	11 to 20 below concern document(s) or information included:						
11. 🔲	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. 🖾	A preliminary amendment.							
14. 🛛	An Application Data Sheet under 37 CFR 1.76.							
15. 🔲	A substitute specification.							
16. 🗌	A pow	er of attorney and/or change of address letter.						
17. 🛛	A com	puter-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.						
18. 🔲	A seco	and copy of the published international application under 35 U.S.C 154(d)(4).						
19. 🔲	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20. 🛭	Other	items or information:						
Expre	ss Mai	l Label No. EV 332086377 US;						

Copy of Published International Application PCT/JP03/07721 (Publication No. WO 03/106663 A1).

DT12 Rec'd PCT/PTO 1 6 DEC 2004

PTO-1390 (Rev. 10-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PPLICATIONANO, dif knowns see 37 CFR 1551

U.S. APPLICATIO	NAVO (if knewn, see 3)	ATTORNEY'S DOCKET NUMBER								
Not yet assig	ineqU/2T(082368-001500US								
21. The following fees are submitted:										
🛛 a) Basic	national fee	\$300.00	<u></u>							
🖾 b) Exam	nination Fee	\$200.00								
C) Searc	ch Fee	\$500.00								
TOTA	L OF ABOVE CALC	\$1000.00								
sequenc	al fee for specification e listing or computer each additional 50 s									
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)			RATE					
- 100 =	/50 =		× \$250.00			\$				
	30.00 for furnishing claimed priority date	\$								
CLAIMS	NUMBER	BER FILED NUMBER EXTRA		RATE		\$				
Total claims	s	17 - 20 =	0	,	x \$50.00	\$0				
Independent da	aims	7 -3 =	4		× \$200.00	\$800.00				
MULTIPLE DEP	ENDENT CLAIM(S)	+ 360.00	\$,						
		\$1800.00								
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.										
		\$1800.00								
_	of \$130.00 for furnish priority date (37 CFF	\$								
			TOTAL	L NA	TIONAL FEE =	\$1800.00				
	g the enclosed assig		\$							
			TOTAL F	EES	ENCLOSED =	\$1800.00	· · · · · ·			
						Amount to be refunded:	\$			
•			Amount to be charged:	\$1800.00						
a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please charge my Deposit Account No. 20-1430 in the amount of \$1800.00 to cover the above fees. A duplicate copy of this sheet is enclosed.										
 c. \text{The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>20-1430</u>. A duplicate copy of this sheet is enclosed. 										
d: Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.										
SEND ALL COR	RESPONDENCE TO	O:	SIGNA	SIGNATURE JUST						
Kevin L. Bastian, Esq. Kevin L. Bastian										
Townsend and T	Townsend and Crew									
Two Embarcade	ro Center, 8th Floor									
San Francisco, (CA 94111	4 STRATION NUMBER								